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Abstract We evaluated blood and fecal biomarkers as in-
dicators of severity in symptomatic patients with confirmed
Clostridium difficile infection (CDI). Recruitment included
patients with CDI based on clinical symptoms and
supporting laboratory findings. Disease severity was defined
by physician’s assessment and blood and fecal biomarkers
were measured. Toxigenic culture done using spore enrich-
ment and toxin B detected by tissue culture were done as
confirmatory tests. Polymerase chain reaction (PCR)
ribotyping was performed on each isolate. There were 98
patients recruited, with 85 (87 %) confirmed cases of toxi-
genic CDI (21 severe, 57 moderate, and seven mild), of
which 68 (80 %) were also stool toxin-positive. Elevated
lactoferrin (p=0.01), increased white blood cell (WBC)
count (p=0.08), and low serum albumin (p=0.03) were all
associated with the more severe cases of CDI. Ribotype 027
infection accounted for 71 % of severe cases (p<0.01) and
patients with stool toxin had significantly higher lactoferrin
levels and WBC counts (p<0.05). Our findings show that
elevated fecal lactoferrin, along with increased WBC count
and low serum albumin, were associated with more severe
CDI. In addition, patients infected with ribotype 027 and
those with stool toxin had significantly higher fecal
lactoferrin and WBC counts.
Introduction
The incidence of Clostridium difficile infection (CDI) is
increasing and estimates are now around 500,000 cases per
year in the U.S., with a yearly cost of 3.2 billion dollars [2, 8,
23, 24]. An epidemic strain, ribotype 027, has been impli-
cated in a number of outbreaks in Europe, Canada, and the
U.S. [2, 6, 10, 12, 13, 36]. This strain has toxin A and toxin B
genes (tcdA and tcdB, respectively), genes for a binary toxin,
18-base-pair tcdC deletion (down regulator for the expres-
sion of toxin), and fluoroquinolone resistance. Studies have
shown that the ribotype 027 strain expresses increased levels
of toxin in vitro, more spores, and is associated with severe
CDI [10, 21, 22, 26].
Identifying actual cases of CDI and determining disease
severity are important factors when recommending a prop-
er course of treatment, including choosing the antibiotic
therapy; metronidazole for mild CDI and vancomycin for
severe CDI [5, 15, 18, 40]. In general, patients with C.
difficile disease often present with fever, have slightly
raised white blood cell (WBC) counts (leukocytosis), and
experience mild to moderate abdominal pain. Most cases
of CDI require discontinuation of inciting antibiotic ther-
apy when possible and the initiation of C. difficile-specific
antimicrobial therapy [5, 18]. Defined laboratory parame-
ters for fulminant C. difficile colitis are WBC count
≥15,000/μL, a rising serum creatinine (50 % increase
and levels ≥2.0 mg/dL), and albumin levels dropping
below 2.5 mg/dL. Clinical complications may involve
pseudomembrane formation, severe abdominal pain and/or
cramping, and colonic thickening observed by computed
tomography (CT) scan. Toxic megacolon stemming from
the ileus may occur, causing nausea, vomiting, severe
dehydration, and extreme lethargy [5, 7, 12, 13, 35].
Currently, no single laboratory parameter or combination
of clinical symptoms is routinely used to stratify patients
based on the severity of CDI for directing therapy.
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Intestinal inflammation is a hallmark of patients with CDI
[13, 35]. The severe stage of CDI, pseudomembranous coli-
tis (PMC), results from the excessive tissue damage and
inflammation. Biomarkers that help determine the “inflam-
matory status” in the intestine of a CDI patient potentially
help predict the severity of CDI and possibly help direct the
choice of antibiotic therapy [16]. Fecal lactoferrin is a bio-
marker for intestinal inflammation and has been evaluated in
both infectious diarrhea and inflammatory bowel disease [9,
11, 16, 30–32, 34, 38]. Previous studies have demonstrated
that elevated lactoferrin occurs in patients with C. difficile
disease [1, 17, 25, 39]. Although these studies identified
increased fecal lactoferrin in patients with CDI, none corre-
lated the significance of levels detected in patients with
defined CDI characteristics in combination with blood bio-
markers for assessing disease severity. Defining a diagnostic
role for blood and fecal biomarkers of inflammation for
stratifying CDI patients according to disease severity would
offer a clinical index for optimizing treatment and improving
patient outcomes.
In this study, we evaluated blood and fecal biomarkers as
indicators of severity in symptomatic patients with confirmed
CDI by toxigenic culture. Patients were stratified by disease
severity according to a physician’s assessment, presence of
ribotype 027 infection, and the detection of stool toxin.
Materials and methods
Study design and fecal specimens
The study protocol and recruiting method was approved by
the institutional review boards (IRBs) of the Summa Health
System (Akron, Ohio) and TechLab, Inc. (Blacksburg, Vir-
ginia). Recruitment was done between February 2010 and
September 2012 using informed consent and included adult
hospitalized patients and outpatients that were identified as
having CDI based on a combination of symptoms, including
≥3 stools per day and in vitro diagnostic testing for glutamate
dehydrogenase (GDH) and stool toxin performed by the
clinical microbiology laboratory at Summa Health System.
Patients with documented enteric infection other than C.
difficile, inflammatory bowel disease, irritable bowel syn-
drome, and celiac disease were excluded. Each patient pro-
vided a single stool specimen for clinical diagnosis and, if
CDI-positive, a portion of this specimen was then shipped to
TechLab, Inc. for tissue culture testing, toxigenic culture,
ribotyping of isolates, and fecal lactoferrin analysis. Stool
testing was done within 72 h of collection by the clinical
laboratory or after a single freeze–thaw at TechLab. Patient
information and stool specimens were coded to maintain
anonymity. Specimen consistency was defined according to
the Bristol Stool Chart as follows: liquid specimens were
defined as type 7; partially formed and soft specimens were
defined as types 4–6; formed specimens were defined as
types 1–3 [19, 22].
Chart reviews and disease assessment
Patient chart reviews were performed to record patient age,
gender, co-morbidities, antibiotic use, treatment outcomes,
reported symptoms, blood analysis for WBC count, and
serum albumin level. Disease severity for CDI was done by
physician’s assessment using the following guidelines: (i)
mild CDI cases included patients of any age, but usually
≤65 years, WBC <15 × 109/L, stool <5 per day, no abdom-
inal, peritoneal, or radiographic signs of disease, no co-
morbid conditions, and able to tolerate oral intake; (ii) mod-
erate CDI cases were of any age, WBC <15 × 109/L, stool ≥5
per day, usually able to tolerate oral intake, reported abdom-
inal complaints, had radiographic or peritoneal signs,
existing co-morbid conditions including but not limited to
renal failure and immunosuppression; (iii) severe CDI cases
involved patients of any age, but was automatically classi-
fied as severe if age ≥65 years, WBC >15 × 109/L, stool ≥10
per day, not able to tolerate oral intake, usually abdominal
complaints, radiographic or peritoneal signs, multiple co-
morbidities including but not limited to renal failure and
immunosuppression.
Tissue culture for toxin B
The C. DIFFICILE TOX-B Test (TechLab® Inc., Blacks-
burg, VA) was performed according to the manufacturer’s
package insert with modification to include a neutral goat
serum control. Briefly, a total of 50 μl of fecal supernatant
was added to each of three wells containing a confluent layer
of human foreskin cells and 50 μl of one of the following:
PBS,C. difficile antitoxin, and neutral goat serum. A positive
cytotoxic effect was defined as greater than 50 % rounding in
the wells containing neutral goat serum and PBS but neu-
tralized with no rounding in wells containing antitoxin.
Qualitative detection of GDH and toxin by immunoassay
The C.DIFF QUIK CHEK COMPLETE™ membrane-based
enzyme-linked immunosorbent assay (ELISA) test
(TechLab® Inc., Blacksburg, VA) was performed according
to the manufacturer’s package insert.
Quantitative fecal lactoferrin
Fecal lactoferrin concentrations were determined by immu-
noassay using the IBD-SCAN® test (TechLab®, Inc., Blacks-
burg, VA). A clinical cut-off of ≥7.25 μg/g stool was used to
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define an elevated level of fecal lactoferrin as an indicator of
intestinal inflammation [11].
Toxigenic culture
The isolation of C. difficile was done using the method
previously described by Boone et al. [4].
PCR analysis and ribotyping
C. difficile isolates were polymerase chain reaction (PCR)
ribotyped using the procedure developed by Stubbs et al. [33].
Statistical analysis
Normal distribution was confirmed prior to analysis. Medi-
an, standard deviation, standard error, and significance were
generated using the JMP 9 (Cary, NC) statistical program by
analysis of variance (ANOVA), Student’s t-test, or the Chi-
square likelihood ratio test, depending upon the data type
examined. Student’s t- test was used when comparing two
independent sets of continuous data with assumed equal
variances. Chi-square was employed to determine the signif-
icance between two groups of categorical data within a
contingency table of a large sample size having only one
degree of freedom. The clinical significance of severe CDI
was determined using one-way ANOVA and expressed as p-
values. A multilinear regression model that included com-
bined patient variables was used to investigate predictors of
severe CDI. For this study, the mean results were reported
with standard error (SE) and significance was defined as
having a p<0.05. The range of levels for each biomarker is
provided as a minimum and maximum (min, max).
Results
A total of 98 patients identified as having CDI based on a
combination of symptoms, history of antibiotic use, stool
GDH, and toxin were enrolled into the study. The mean
age was 67 years and 64 % were female (Table 1). There
were 85 (87 %) confirmed cases of toxigenic CDI using
toxigenic culture, of which 68 (80 %) had stool toxin detect-
ed by the tissue culture assay. Of these, 38 (45 %) were
infected with ribotype 027. One patient had a mixed infec-
tion of toxigenic and nontoxigenic C. difficile based on the
isolation of a nontoxigenic ribotype (009) in combination
with the detection of stool toxin by the tissue culture assay.
This patient was admitted directly from an extended-care
facility and had previous antibiotic therapy. Fecal lactoferrin
(15 μg/g) and WBC count (11.9 × 109/L) were slightly
elevated and the serum albumin level was low (2.4 mg/dL).
Repeat bacterial culture never produced a toxigenic isolate.
Six patients (6 %) were negative for stool toxin and colo-
nized with nontoxigenic isolates, as demonstrated by the
isolation of nontoxigenic ribotypes, including 009 (1), 010
(1), 038 (2), and 039 (2). Repeated attempts to isolate a
toxigenic ribotype were unsuccessful. The remaining six
patients were negative for C. difficile by both bacterial cul-
ture and tissue culture. Additional patient characteristics
including reported symptoms, co-morbidity, and treatment
history are listed in Table 1.
Patients infected with toxigenic C. difficile were stratified
according to physician’s assessment for disease severity,
resulting in 21 severe cases, 57 moderate cases, and seven
mild cases. Age, reported abdominal pain, number of stools
per day, blood, and fecal biomarkers were evaluated between
severity groups and the results are shown in Table 2. Patients
who suffered with clinically severe CDI had significantly
elevated lactoferrin, higher WBC counts, and lower serum
albumin when compared to those cases with moderate and
mild clinical disease. In addition, we evaluated the clinical
impact for blood and fecal biomarkers with severe CDI using
one-way ANOVA. We identified a significant impact
(p<0.05) for increased lactoferrin, high WBC count, low
serum albumin, and ribotype 027 infection for severe CDI
(Table 2). In addition, we utilized a multilinear regression
model that included age, presence of pain, stool toxin,
lactoferrin, serum albumin, WBC count, and stools per day
to investigate predictors of severe CDI. The model showed a
significant association between these variables and severe
CDI (p=0.0175). The effect weight for each variable in the
model expressed as a p-value is shown Table 3. Of the bio-
markers included in the model, lactoferrin and serum albu-
min levels were highly significant (p<0.05) and the WBC
count trended close to being significant (p=0.0802).
In our population, we had an overall 027 infection rate of
45 %, with the next four most common non-027 toxigenic
ribotypes being 014 (8 %), 106 (5 %), 002 (5 %), and 126
(4 %). There were six non-027 isolates that were nontoxigenic
and these patients were not included in the analysis for eval-
uating disease severity. There was a significant difference for
elevated lactoferrin (p=0.012) and for lower serum albumin
levels (p=0.003) between 027-infected patients compared to
other toxigenic non-027-infected patients. Age, WBC count,
number of stools per day, and reported abdominal pain were
similar between the ribotype groups.
Testing for stool toxin by tissue culture showed that 80 %
of patients infected with a toxigenic ribotype had detectable
toxin. When patients were stratified based on the presence of
stool toxin, toxin-positive patients had significantly higher
lactoferrin (p=0.019) and WBC count (p=0.029), and the
serum albumin levels trended lower (Table 4). The number
of toxin-positive patients reporting abdominal pain trended
towards significance (p=0.054) and there was a significantly
higher number of toxin-positive patients with ribotype 027
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infection (p=0.044). There were a total of 19 patients that
required additional antibiotics for their CDI episode and
90 % of these patients had stool toxin and 68 % of them
were infected with ribotype 027. For this group, the mean±-
SE for lactoferrin, WBC count, and serum albumin was
566±261, 17.1±3.8, and 2.3±0.2, respectively. No differ-
ence was observed between groups for age and the number
of stools per day. When stratified by gender, male patients
were significantly more likely to be stool toxin-positive
compared to female patients (p=0.002). Of the patients with
detectable stool toxin, the levels of lactoferrin ranged from 1
to 4,672 μg/g feces, and only 3 (4 %) patients had normal
fecal lactoferrin levels (<7.25 μg/g feces). For patients that
were negative for stool toxin, 41 % had normal lactoferrin
and all but a single patient had levels below 85 μg/g feces.
Table 1 Patient demographics and culture results for the study popu-
lation. The percentage of patients for each criterion is shown, along with





Gender Female 64 % (63)
Age >64 years 62 % (61)
Mean age 67 years
Co-morbidity Pulmonary disease 42 % (41)
Diabetes 33 % (32)
Coronary disease 31 % (30)
Kidney disease 25 % (24)
Cancer 24 % (23)
Symptoms Abdominal pain 60 % (59)
Fever 32 % (31)
Stool mucus 23 % (22)
Stool blood 12 % (12)
Stool consistency at
assessment
Bristol 6–7 (unformed) 62 % (61)
Bristol 4–5 (soft formed) 36 % (35)
Bristol 1–3 (hard formed) 2 % (2)
Overall clinical condition Severe 25 % (24)
Moderate 67 % (66)
Mild 8 % (8)
Patient history Antibiotics 75 % (73)
Antibiotics and CDI 14 % (14)
No prior antibiotics 10 % (10)
CDI with no antibiotics 1 % (1)
Culture Toxigenic CDI 87 % (85)
Nontoxigenic CDI 6 % (6)
Mixed 1 % (1)
No growth 6 % (6)
Ribotype 027 45 % (38)
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Discussion
In this study, we examined blood and fecal biomarkers for
assessing disease severity in patients with CDI. We measured
two commonly used blood parameters for assessing disease
severity in CDI, WBC count and serum albumin level, for
comparison with fecal lactoferrin levels as an indicator of
intestinal inflammation. C. difficile-specific diagnostic bio-
markers including GDH, toxin B, and ribotype 027 isolates
were also measured. Our results showed significantly more
inflammation as determined by increased WBC counts
(peripheral) and elevated fecal lactoferrin (intestinal) for pa-
tients with clinically assessed moderate to severe CDI. Serum
albumin was lower in patients with more severe disease,
indicating a damaged mucosa, resulting in the loss of serum
protein into the bowel. A multilinear regression model exam-
ining the relationship of clinical symptoms and biomarkers on
disease severity indicated a strong association for severe CDI
(p=0.0175). In addition, the fecal lactoferrin and blood bio-
markers, WBC count and low serum albumin level showed a
significant association within severe CDI (p<0.05). Further
studies are needed for evaluating the combination of fecal
lactoferrin and blood biomarkers with symptoms and patient
characteristics for developing a sensitive and specific disease
severity index for stratifying CDI patients for optimal treat-
ment and disease management.
Another important finding of our study is the clinical
importance of determining stool toxin as an indicator of
disease. Our results showed that elevated biomarkers of
inflammation, WBC count and lactoferrin, were associated
with the presence of stool toxin. Patients with clinically
assessed severe and moderate CDI were more often likely
to have a positive stool toxin (80 %). The combination of
stool toxin and increased intestinal inflammation as shown
by increased lactoferrin is not an unexpected finding be-
cause: (i) both toxins A and B are strong chemotactic proteins
that cause the release of IL-8 and the infiltration of activated
neutrophils into the intestinal mucosa [29]; (ii) toxin A also
stimulates other pro-inflammatory cytokines, including IL-1β
and tumor necrosis factor alpha (TNF), while toxin B is a
cytotoxin that causes both tissue damage and inflammation
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damaging and chemotactic activities of toxins A and B contrib-
ute to the severity of CDI [29]. Recently, Planche et al. analyzed
12,420 specimens from 10,691 patients using the reference
assays toxigenic culture and tissue culture assay for stool toxin.
Patients with stool toxin had a significantly highermortality rate
(16.6 %) compared to the toxigenic culture-positive only
(9.7 %; p=0.022) and C. difficile-negative groups (8.6 %;
p=0.001). In addition, the stool toxin-positive patients had
significantly higher (p=0.001) WBC counts compared to the
other two groups. Based on these results, Planche et al. con-
cluded that patients having a positive stool toxin have C.
difficile disease with an increased risk of mortality [27]. Con-
sidering our findings along with the Planche et al. study, a
method for determining the presence of intestinal inflammation
in combination with the presence of toxin in stool identifies
patients with severe CDI. In addition, even though quantifying
the amount of toxin in the stool was beyond the initial scope of
this study, future work should consider measuring the level of
toxins A and B and the correlation of amounts to biomarkers of
inflammation and severity of disease.
A new finding from this study is the correlation of increasing
fecal lactoferrin levels with increasing severity of clinically
assessed CDI. Lactoferrin levels showed over a 5-fold increase
in patients classified as severe CDI compared to moderate
disease. Multiple studies have demonstrated increased WBC
count as a useful indicator of severity in CDI; however, it is
worth noting that these counts are not specific for intestinal
inflammation and may be increased by inflammatory co-
morbidities. Fecal lactoferrin is a glycoprotein that is present
in most mucosal secretions and a primary component of the
granules of activated neutrophils; thus, it is a specific marker of
intestinal inflammation. During the onset of intestinal inflam-
mation caused by C. difficile, activated neutrophils infiltrate the
intestinal lumen, causing an increase in fecal lactoferrin [9, 11].
Our results support a role for assessing patients with CDI using
fecal lactoferrin as an indicator of intestinal inflammation and
then using the amount as an aid for stratifying patients based on
disease severity. In addition, a biomarker like fecal lactoferrin
may offer the utility for monitoring disease activity in patients
with CDI as an indicator of response to medical treatment and
for predicting a relapse.
The emergence of ribotype 027, which has been shown to
express in vitro, more toxin, and production of increased
spores has been linked to numerous outbreaks involving
more severe C. difficile disease and a greater chance of
relapse compared to other known ribotypes [10, 12, 21, 22,
26]. However, some recent studies have shown no link
between the infecting ribotype and more severe clinical
disease and worse outcomes, raising questions on the clinical
significance, in terms of severity, of an 027 infection [3, 23,
37]. In our study population, we had 45 % of patients with
toxigenic C. difficile infected with ribotype 027. These pa-
tients were more likely to be assessed as severe by the
physician and had significantly higher lactoferrin indicating
more intestinal inflammation, lower serum albumin levels,
and a higher frequency of positive stool toxin (92 %). More
research is needed in order to determine the in vivo produc-
tion of increased stool toxin in patients infected with 027 as a
virulence factor causing more inflammation, resulting in
severe CDI.
In conclusion, our results show increased fecal lactoferrin,
higher WBC counts, and lower serum albumin levels in CDI
patients who have severe clinical disease. The presence of
stool toxin was associated with increased inflammation for
moderate and severe cases. In addition, we confirmed that
older, sicker patients with ribotype 027 CDI are more likely
to be stool toxin-positive, resulting in increased intestinal
and peripheral inflammation, as indicated by higher levels of
fecal lactoferrin and WBC counts, respectively. Future stud-
ies are needed in order to evaluate the optimization of treat-
ment based on a clinical index for severity that combines
patient characteristics with fecal and blood biomarkers in
patients infected with C. difficile.
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